Key Highlights

  • SkinHealth Systems (NASDAQ:SKIN) was trading up 40.39% at USD 14.53 on Friday, November 6, 2026, a day after reporting third-quarter results, with a prior close near USD 10.35 (calculated).
  • Third-quarter net sales were USD 69.2 million, down 2.1% from USD 70.7 million, while the net loss narrowed to USD 0.9 million from USD 11.0 million a year earlier.
  • Adjusted EBITDA rose to USD 13.4 million, a 19.3% margin, from USD 8.9 million, a 12.6% margin; 2026 guidance is net sales of USD 281 million to USD 287 million.
  • Cash fell to about USD 112 million from about USD 233 million at year-end after USD 103.2 million of 2026 notes were repaid on September 30, 2026.

Narrower Loss and Higher EBITDA Follow the Third-Quarter Report

SkinHealth Systems (NASDAQ:SKIN), the company formerly known as The Beauty Health Company, reported third-quarter 2026 results on November 5, 2026 after the close. Net sales were USD 69.2 million, down 2.1%, as delivery system shipments fell to 798 units from 875. The net loss was USD 0.9 million against USD 11.0 million a year earlier, and adjusted EBITDA reached USD 13.4 million. The company, whose flagship Brand is Hydrafacial, sells medical aesthetics devices and consumables. Shares were trading up 40.39% at USD 14.53 the next day. The release does not explain the share reaction, so the link between the two is an inference from timing.

Guidance, Debt Repayment and the 1-for-20 Reverse Split

The company updated 2026 guidance to net sales of USD 281 million to USD 287 million and adjusted EBITDA of USD 48 million to USD 50 million. The release does not state the earlier range, so whether guidance was raised cannot be confirmed. A 1-for-20 reverse split of Class A common stock took effect on October 14, 2026, cutting shares outstanding from about 130.3 million to about 6.5 million, a step taken to regain compliance with Nasdaq's USD 1.00 minimum bid rule. At USD 14.53, that share count implies Equity value near USD 94 million (calculated, using the October 7 count). Second-quarter net sales of USD 72.1 million were 7.79% lower than a year earlier.

Cash Drawdown, Convertible Notes and a Class Action Settlement

The cash line deserves attention. Cash, equivalents and restricted cash fell to about USD 112 million from about USD 233 million at December 31, 2025, as the remaining USD 103.2 million of 2026 notes was repaid on September 30. Convertible senior notes of USD 243.0 million remain on the balance sheet, including 7.95% secured notes due November 15, 2028. The company also moved Australia, New Zealand and China to distributor partners, launched SkinStylus in six European markets and disclosed a proposed settlement of a securities class action. Declining unit sales, Leverage and a thinly floated post-split share count could keep the stock volatile.

Where Things Stand

A 40.39% pop is possible but not guaranteed to hold. SkinHealth Systems (NASDAQ:SKIN) delivered a near break-even quarter with higher adjusted EBITDA and issued updated full-year guidance, which gives the move a data-backed reason, although no company statement ties the two. Against that, net sales are shrinking, cash dropped by about half after debt repayment, and the post-reverse-split share count is only about 6.5 million, so price swings can be large in both directions. Watch fourth-quarter shipments, the settlement terms and any further guidance changes.